PhoreMost
A new-model drug discovery company based in Cambridge, UK.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $11.8m Valuation: $230m | Series B | |
| Total Funding | 000k | ||
| GBP | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (30 %) | 38 % | 13 % | 55 % | (12 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (542 %) | (1036 %) | (1216 %) | (1093 %) | (857 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (264 %) | (678 %) | (692 %) | (989 %) | (719 %) | (946 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 469 % | 708 % | - | - | - |
Source: Company filings or news article
Related Content
PhoreMost is a biotechnology company focused on expanding the druggable space through its innovative drug target identification platform. The company operates in the pharmaceutical and biotechnology markets, primarily serving clients involved in drug discovery and development. PhoreMost collaborates with leading organizations, such as Oxford Biomedica and XtalPi, to discover and develop next-generation therapies, including targeted protein degradation and gene therapy solutions. The business model revolves around partnerships and collaborations, leveraging its platform to identify first-in-class drug targets in areas of high unmet need, particularly in oncology and neurodegenerative disorders. PhoreMost generates revenue through research collaborations, licensing agreements, and milestone payments from its partners. The company is driven by a team of scientists and biotechnology professionals, led by an experienced management team passionate about advancing medical science.
Keywords: drug target identification, biotechnology, oncology, neurodegenerative disorders, gene therapy, AI collaboration, protein degradation, drug discovery, partnerships, licensing.